Targeting Persistent Neuroinflammation after Hypoxic-Ischemic Encephalopathy-Is Exendin-4 the Answer?

Area of Science:

• Neonatal neurology
• Neuroscience
• Pharmacology

Background:

• Hypoxic-ischemic encephalopathy (HIE) causes significant newborn brain injury.
• Therapeutic hypothermia is the sole approved treatment, reducing mortality and disability.
• Persistent neuroinflammation post-hypothermia contributes to ongoing deficits.

Purpose of the Study:

• To explore Exendin-4 as an adjunctive therapy for HIE.
• To investigate Exendin-4's potential to mitigate persistent neuroinflammation.
• To evaluate Exendin-4's neuroprotective effects in perinatal brain injury models.

Main Methods:

• Review of preclinical and clinical studies on HIE and therapeutic hypothermia.
• Analysis of in vitro and in vivo data on Exendin-4's pharmacological effects.
• Examination of limited studies on Exendin-4 in neonatal hypoxic-ischemic brain injury models.

Main Results:

• Exendin-4 demonstrates anti-inflammatory, mitochondrial protective, anti-apoptotic, anti-oxidative, and neurotrophic properties in various models.
• A neonatal mouse study showed promising neuroprotective effects of Exendin-4.
• Despite hypothermia, approximately 29% of infants with HIE still experience disability, indicating a need for additional therapies.

Conclusions:

• Exendin-4 shows potential as an additive treatment to therapeutic hypothermia for HIE.
• Targeting persistent neuroinflammation with Exendin-4 may improve outcomes.
• Further research, including large animal models, is needed to confirm Exendin-4's safety and efficacy as an adjunct therapy.